This article is provided for general information purposes only and does not constitute medical advice. I am not a medically qualified professional, and the content should not be relied upon as a substitute for professional medical guidance. Always consult a GP or healthcare provider before starting any medication or weight management programme.

Mounjaro History – Injectable Treatment

Origins of Mounjaro : Why was it developed?

Mounjaro (tirzepatide) was designed by Eli Lilly & Company as the first single-molecule agonist able to stimulate both the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. Lilly’s scientists theorised that combining the two “incretin” pathways would deliver stronger glucose-lowering and weight-loss effects than GLP-1 drugs alone. Early laboratory work in the mid-2010s produced the peptide then known as LY3298176. In 2018 the discovery and first-in-human data were published [source], confirming powerful metabolic and appetite-suppressing activity.

Key Development Milestones for Mounjaro

  • 2015-2017: Pre-clinical optimisation: Lilly engineers a 39-amino-acid GIP backbone with a C20 fatty-diacid side chain, giving once-weekly dosing and dual-receptor affinity.
  • Oct 2018: Phase 1 proof-of-concept: First human data show dose-dependent HbA 1c and weight reductions.
  • 2018-2021: SURPASS Phase 3 programme: Five global trials (SURPASS-1 to -5) test 5 mg, 10 mg and 15 mg once weekly against semaglutide 1 mg, insulin degludec and insulin glargine, consistently showing superior glucose and weight outcomes.
  • 13 May 2022: FDA approval for type 2 diabetes: The US FDA clears tirzepatide as Mounjaro for adults whose blood sugar is uncontrolled on diet ± medication.
  • 8 Nov 2023: UK authorisation for weight loss: The MHRA grants a national licence extending Mounjaro’s indications to weight management in adults with BMI ≥ 30, or 27-30 with comorbidities.
  • 9 Nov 2023: FDA approval for chronic weight management: Under the brand Zepbound, tirzepatide gains a separate licence for adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) plus a weight-related condition.

Mounjaro Ownership, Patents & Licensing

Eli Lilly owns the global rights to tirzepatide and markets it as Mounjaro (diabetes) and Zepbound (weight management). The core composition-of-matter patent (US 9 474 780) runs until 2036, with additional formulation / device patents extending protection to 2039. No authorised generic versions are expected in the US, UK or EU before those dates. Lilly has, however, granted licensed copies in certain emerging markets, while continuing legal action against unauthorised knock-offs to protect Mounjaro.

Why is Mounjaro & Tirzepatide significant?

Its “twincretin” mechanism delivers the greatest average weight-loss and HbA1c reductions yet seen with an incretin-based therapy, setting a new benchmark for both diabetes control and obesity treatment. As demand surges, Lilly is scaling up manufacturing and defending its patent estate while global regulators weigh access and cost considerations.

How Does Mounjaro Work?

Mounjaro is a once-weekly, subcutaneous (under the skin) injection that acts as a dual incretin agonist, meaning one molecule stimulates two separate hormone receptors:

  • GIP Receptor: glucose-dependent insulinotropic polypeptide
  • GLP-1 Receptor: glucagon-like peptide-1

The twin-hormone approach

Traditional weight-loss and diabetes injectables (eg. semaglutide) target only GLP-1. Tirzepatide’s additional action on the GIP pathway creates a complementary, and in many patients additive, metabolic effect.

Main metabolic actions

  • Enhances glucose-dependent insulin release, both GIP and GLP-1 receptors on the pancreas trigger a stronger, more physiological insulin surge after meals while reducing glucagon secretion. This lowers post-prandial and fasting blood sugar.
  • Slows gastric emptying, food stays in the stomach longer, flattening glucose spikes and prolonging satiety.
  • Suppresses appetite, both receptors are expressed in the brain’s hypothalamus and reward centres, dampening hunger signals and food cravings.
  • Promotes fat utilisation, emerging data suggest GIP signalling may boost adipocyte lipolysis, adding to the weight-loss effect.

Dose-response and timing

Because tirzepatide is fatty-acid–modified, it binds to albumin in the bloodstream, giving a half-life of roughly five days. This allows once-weekly dosing that is titrated from 2.5mg up to the maximum 15mg dose. Patients typically notice a reduction in appetite within the first fortnight; measurable weight loss often appears after four to eight weeks and becomes most pronounced at 40–72 weeks on a stable dose.

In short, Mounjaro works by tackling both blood-sugar regulation and energy balance through its dual GIP/GLP-1 activity, producing larger average weight and HbA1c reductions than single-hormone therapies.

We have a number of articles on this topic, specifically aimed at cyclists, so check them out of you’re looking for more info; Cycling on Mounjaro and Exercising on Mounjaro

Mounjaro Weight Loss